Pluri Inc. Stock

Equities

PLUR

US72942G2030

Biotechnology & Medical Research

Delayed Nasdaq 12:03:41 2024-05-06 pm EDT 5-day change 1st Jan Change
5.8 USD +0.87% Intraday chart for Pluri Inc. +8.92% +23.81%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 234K Sales 2023 287K Capitalization 32.98M
Net income 2022 -41M Net income 2023 -28M EV / Sales 2022 58 x
Net cash position 2022 26.21M Net cash position 2023 10.27M EV / Sales 2023 79.1 x
P/E ratio 2022
-0.96 x
P/E ratio 2023
-1.04 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 76.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.13%
1 week+8.92%
Current month+2.50%
1 month+2.50%
3 months-0.33%
6 months+26.16%
Current year+23.81%
More quotes
1 week
5.14
Extreme 5.14
5.90
1 month
4.71
Extreme 4.71
6.26
Current year
4.16
Extreme 4.16
8.48
1 year
3.45
Extreme 3.4488
8.56
3 years
3.45
Extreme 3.4488
36.40
5 years
3.45
Extreme 3.4488
106.32
10 years
3.45
Extreme 3.4488
302.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 06-10-31
Director of Finance/CFO 40 13-04-30
Chairman 70 05-09-25
Members of the board TitleAgeSince
Director/Board Member 73 21-07-14
Director/Board Member 55 23-07-10
Chairman 70 05-09-25
More insiders
Date Price Change Volume
24-05-06 5.8 +0.87% 12 296
24-05-03 5.75 +1.95% 6,359
24-05-02 5.64 +5.03% 40,372
24-05-01 5.37 -4.10% 21,388
24-04-30 5.6 +6.26% 35,048

Delayed Quote Nasdaq, May 06, 2024 at 12:03 pm EDT

More quotes
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW